

IN THE CLAIMS

Please amend the claims as follows:

1-34. (Canceled)

35. (Previously Presented) 3,11b-*cis*-dihydropyridazinone or a salt thereof.

36. (Previously Presented) A composition consisting of 3,11b-*cis*-dihydropyridazinone, or a salt thereof, in substantially pure form.

37. (Previously Presented) 3,11b-*cis*-dihydropyridazinone or a salt thereof according to claim 35 which is in a (+)-isomeric form.

38. (Previously Presented) A composition comprising 3,11b-*cis*-dihydropyridazinone or a salt thereof, the composition being substantially free of 3,11b-*trans*-dihydropyridazinone.

39. (**Currently Amended**) A composition comprising 3,11b-*cis*-dihydropyridazinone or a salt thereof with ~~and containing~~ less than 5% of 3,11b-*trans*-dihydropyridazinone.

40. (**Currently Amended**) The[[A]] composition according to claim 38 wherein the 3,11b-*cis*-dihydropyridazinone or the[[a]] salt thereof is a (+)-isomer.

41. (**Currently Amended**) The[[A]] composition according to claim 39 wherein the 3,11b-*cis*-dihydropyridazinone or the[[a]] salt thereof is a (+)-isomer.

42. (**Currently Amended**) The 3,11b-*cis*-dihydropyridazinone or a salt thereof according to claim 35 in the form of a 2*S*,3*S*,11*bR* isomer having the formula (Ia):




43. **(Currently Amended)** The 3,11b-*cis*-dihydrotetrabenazine or a salt thereof according to claim 35 in the form of a 2*R*,3*R*,11*bS* isomer having the formula (Ib):



44. **(Currently Amended)** The 3,11b-*cis*-dihydrotetrabenazine or a salt thereof according to claim 35 in the form of a 2*R*,3*S*,11*bR* isomer having the formula (Ic):



45. (Currently Amended) The 3,11b-*cis*-dihydrotetrabenazine or a salt thereof according to claim 35 in the form of a 2*S*,3*R*,11b*S* isomer having the formula (Id):



46. (Currently Amended) The 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of a free base.

47. (Currently Amended) The 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of an acid addition salt.

48. (Currently Amended) The[[An]] acid addition salt of 3,11b-*cis*-dihydrotetrabenazine according to claim 47 wherein the salt is a methane sulphonate salt.

49. (Previously Presented) A pharmaceutical composition comprising 3,11b-*cis*-dihydrotetrabenazine or a salt thereof and a pharmaceutically acceptable carrier.


50. (Currently Amended) The[[A]] pharmaceutical composition according to claim 49 wherein the 3,11b-*cis*-dihydrotetrabenazine or a salt thereof is a (+)-isomer.

51. (Withdrawn-Previously Presented) A method for the prophylaxis or treatment of a hyperkinetic movement disorder, which method comprises the administration of an

effective prophylactic or therapeutic amount of 3,11b-*cis*-dihydrotetrabenazine or a salt thereof.

52. **(Withdrawn-Currently Amended)** ~~The~~[[A]] method according to claim 51 wherein the hyperkinetic movement disorder is selected from Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome.

53. **(Withdrawn-Currently Amended)** A process for preparing 3,11b-*cis*-dihydrotetrabenazine, which process comprises the reaction of a compound of ~~the~~ formula (II):



with a reagent or reagents suitable for hydrating the 2,3-double bond in the compound of formula (II) and thereafter ~~where required~~ separating and isolating a desired 3,11b-*cis*-dihydrotetrabenazine isomer form.


54. **(Withdrawn-Currently Amended)** A process for preparing 3,11b-*cis*-dihydrotetrabenazine, which process comprises subjecting a compound of ~~the~~ formula (III):



55. (Withdrawn-Previously Presented) A compound of the formula (II):




56. (Withdrawn-Previously Presented) A compound of the formula (III):




or a salt thereof.


57. (Previously Presented) A Mosher's acid ester of 3,11b-*cis*-dihydropyridazine.
58. (New) The 3,11b-*cis*-dihydropyridazine or a salt thereof according to claim 35, which consists of greater than 90% 3,11b-*cis*-dihydropyridazine, or a salt thereof.
59. (New) A composition comprising 3,11b-*cis*-dihydropyridazine, or a salt thereof, and a pharmaceutically acceptable carrier, wherein the 3,11b-*cis*-dihydropyridazine, or a salt thereof, consists of greater than 90% 3,11b-*cis*-dihydropyridazine, or a salt thereof.
60. (New) The composition of claim 59, containing less than 5% of 3,11b-*trans*-dihydropyridazine.
61. (New) The composition of claim 59, wherein the 3,11b-*cis*-dihydropyridazine is a (+)-isomer, or a salt thereof.
62. (New) The composition of claim 59, wherein in the 3,11b-*cis*-dihydropyridazine is a 2*S*,3*S*,11*bR* isomer having the formula (Ia), or a salt thereof:




63. (New) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a 2*R*,3*R*,11b*S* isomer having the formula (Ib), or a salt thereof:



64. (New) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a 2*R*,3*S*,11b*R* isomer having the formula (Ic), or a salt thereof:



65. (New) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a 2*S*,3*R*,11b*S* isomer having the formula (Id), or a salt thereof:



(Id).

66. (New) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine is a free base.

67. (New) The composition of claim 59, wherein in the 3,11b-*cis*-dihydrotetrabenazine, or a salt thereof is in the form of an acid addition salt.

68. (New) The composition of 67, wherein the acid addition salt is a methane sulphonate salt.